Pamezol (Esomeprazole)

Esomeprazole is a proton pump inhibitor that acts on acid‑related gastrointestinal conditions.

• Gastro‑oesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis.
• Peptic ulcer disease: supports ulcer healing and reduces recurrence risk.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the condition.

• Esomeprazole selectively inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) located on the parietal cell surface of the stomach, blocking the final step of acid secretion. This results in a sustained increase in gastric pH, allowing damaged mucosa to heal and reducing acid‑related symptoms.

Adverse reactions to esomeprazole are generally mild to moderate and vary with individual sensitivity.

Common Side Effects

• Headache: mild and transient.
• Diarrhea: usually self‑limiting.
• Nausea: occasional and mild.
• Abdominal pain: intermittent discomfort.
• Flatulence: excess gas.
• Constipation: occasional bowel change.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): requires immediate medical attention.
• Clostridioides difficile infection: may cause severe colitis.
• Low magnesium levels (hypomagnesemia): can lead to muscle cramps or arrhythmias.
• Fracture risk: long‑term use may be associated with increased bone fracture risk.
• Liver enzyme elevation: may indicate hepatic stress.
• Stevens‑Stevens Johnson syndrome: rare but serious skin reaction.

When prescribing esomeprazole, clinicians should consider several safety aspects.

• Assess renal function: dose adjustment may be required in severe impairment.
• Review concomitant medications: potential for drug‑drug interactions.
• Monitor for magnesium levels: especially during prolonged therapy.
• Evaluate bone health: consider calcium/vitamin D supplementation for long‑term users.
• Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Esomeprazole can affect the absorption and metabolism of several co‑administered drugs.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect may increase cardiovascular risk.
• Atazanavir: decreased antiviral efficacy due to reduced gastric acidity.
• Methotrexate (high dose): increased systemic exposure and toxicity.

Moderate Interactions (Monitor Closely)

• Warfarin: potential alteration of INR values.
• Digoxin: may increase serum concentrations.
• Phenytoin: possible reduction in serum levels.
• Ketoconazole: reduced absorption requiring dosage adjustment.